Hansoh ends collaboration with Silence; Vir hunts for HBV drug partner
Plus, news about Alopexx, Medigene, EpimAb and Belite Bio: Hansoh backs out of siRNA pact with Silence Therapeutics: The London-based biotech said Hansoh has decided not to ...
View ArticleTeladoc reports $1B net loss as it works to turn around its business
Teladoc wrapped up its financial year with a $1 billion net loss and disappointing results as the telehealth giant continues to work on its turnaround strategy. The net loss was in a big part due ...
View ArticleVerve is latest gene editing company to suffer setback, as Vertex walks away...
Verve Therapeutics has not escaped the doom that seems to be engulfing the gene editing sector of late. The company said Thursday that Vertex Pharmaceuticals handed back the rights to a ...
View ArticleOpenAI meets cancer care
Most healthcare organizations have been using AI for decidedly unglamorous tasks like documentation and billing. Now we’re starting to see how it could be used in clinical care. Color Health and OpenAI...
View ArticleDrug policy veteran at CMS to depart on Friday
John Coster, CMS' senior technical advisor for the Medicare drug rebate and negotiation group, told Endpoints News that he's leaving his agency on Friday. Coster, who has been at CMS for more than a...
View ArticlePharma-backed Mission Therapeutics stops preclinical operations, focuses on...
Clinical-stage biotech Mission Therapeutics is closing its preclinical laboratory operations in Cambridge, UK, a spokesperson confirmed to Endpoints News. The biotech will focus on its clinical...
View ArticleHHS’ vaccine injury panel in limbo after monthlong meeting delay
More than a month after its most recent scheduled meeting was postponed, a panel advising the government on a federal compensation program for vaccine injuries has no information on when its operations...
View ArticleCDC investigating hospitalizations after chikungunya vaccination
The CDC is looking into a handful of hospitalization cases after people got Ixchiq, Valneva’s vaccine for chikungunya, according to a notice posted to the CDC’s webpage. The notice, posted Tuesday ...
View ArticleLilly joins molecular glue field with Magnet deal worth up to $1.25B
Another day, another molecular glue deal in the biopharma world. This time around, it’s Eli Lilly partnering with the private startup Magnet Biomedicine on the technology. Lilly will pay up to $40...
View ArticlePfizer vet William Pao’s next venture; Sanofi’s computational science exec...
William Pao, a longtime R&D leader at Roche who briefly held the chief development officer post at Pfizer until the summer of 2023, has been stealthily leading a biotech ...
View ArticleTrump’s science crackdown hits rare disease research: ‘We need to sit down...
Jill Wood had pinned her hopes on a little-known federal program to fund her son’s gene therapy. The initiative, which awards vouchers to companies targeting rare pediatric diseases, offered her son a...
View ArticleBridgeBio oncology spinout to go public via combination with SPAC from...
The second blank-check vehicle from Cormorant's Bihua Chen plans to take BridgeBio's oncology spinout onto the Nasdaq. The special purpose acquisition company — known as Helix Acquisition Corp. II —...
View ArticlePacira absorbs GQ Bio for $32M; Layoffs at BMS, Eisai and CRISPR Therapeutics
Plus, news about Recursion, Nxera, Viatris and DualityBio: Pacira BioSciences takes on GQ Bio: The non-opioid pain biotech is spending $32 million to buy the remaining ...
View ArticlePraxis' essential tremor drug fails interim Phase 3 readout
Praxis reported that its lead small molecule program failed a Phase 3 study on Friday morning, sending its stock price {$PRAX} down roughly 40%. The company was studying whether an experimental drug...
View ArticleInfectious disease doctors consider 'mini-ACIP' if RFK erodes CDC vaccine panel
Infectious disease professionals, bracing for an overhaul of the CDC's vaccine advisory group, are in discussions to stand up a parallel committee of experts outside of government, Endpoints News has...
View ArticleCHMP recommends Regeneron, Novartis drugs that still await FDA approval
The European Medicines Agency’s human medicines committee (CHMP) has recommended four new drugs for approval, including Regeneron's Lynozyfic for the treatment of relapsed and refractory multiple...
View ArticleBipartisan 'pill penalty' fix and other bills vie for inclusion in...
Industry groups are looking to push government drug price negotiation and PBM reforms into a massive Republican domestic policy bill that will likely pass on party lines. PhRMA and a nonprofit ...
View ArticleAt least six drugmakers say they will participate in round two of IRA...
At least half of drugmakers have agreed to participate in the second round of Medicare price negotiations amid ongoing legal battles and uncertainty surrounding the new administration’s stance on the...
View ArticleThe top 100 biotech investors; FDA vaccine meeting canceled; Can Bill...
Good morning and rabbit rabbit as we begin the month of March. It was another busy week in the world of biopharma so let’s jump straight into the headlines. John Carroll examined the last year ...
View ArticleLexicon plots Phase 3 trial for diabetic pain drug despite mid-stage flop
Lexicon Pharmaceuticals’ non-opioid drug has failed a mid-stage test in a chronic pain indication — but the company says there’s still a path forward and even potential partnership opportunities for...
View Article